The IDEATE: IPILIMUMAB DRUG EVALUATION brand, founded in 2010 (United States), from 496 sister brands and 17478 competing brands. The IDEATE: IPILIMUMAB DRUG EVALUATION brand is owned by BRISTOL-MYERS SQUIBB COMPANY, a company listed in New York. IDEATE: IPILIMUMAB DRUG EVALUATION belongs to the Drug Manufacturers business sector.

IDEATE: IPILIMUMAB DRUG EVALUATION is a brand of BRISTOL-MYERS SQUIBB COMPANY (BMY) Sustainability

International deposit : 2010 Business sector Drug Manufacturers
Here is the evolution of interest in BRISTOL-MYERS SQUIBB COMPANY "sustainability" criteria around the world over the past five years. The graph shows the evolution of the search rate over time, where the value 100 indicates the week with the most searches.
What is the brand's web response on its sustainability
Result of Google's query: "IDEATE: IPILIMUMAB DRUG EVALUATION sustainability"
Sustainability -> Share price